Search - tctmd.com

Displaying 1 - 20 of 73

Sort: Relevancy | Date

Presentation EuroPCR 2025

Final seven-year outcome of the COMPARE-ABSORB trial

Presenter: Pieter Smits

May 22, 2025

Presentation

Myocardial Blood Flow and Coronary Flow Reserve 3 Years After Absorb BVS vs DES: VANISH

April 30, 2019

Presentation ESC 2018

ISAR-Absorb MI: A Prospective, Randomized Trial of BVS vs EES in Patients Undergoing Coronary Stenting for Myocardial Infarction

Presenter: Robert Byrne

August 29, 2018

Presentation ESC 2018

Outcomes of 10.312 Patients Treated with Everolimus-eluting Bioresorbable Scaffolds During Daily Clinical Practice: Results from the European Absorb Consortium

Presenter: Holger M. Nef

August 29, 2018

Presentation JIM 2018

New Fully Absorbable Patch Based Large Hole Vascular Closure Device

Presenter: Michael Laule

February 23, 2018

Presentation

Mid- and Long-term Outcome Comparisons of Absorb BVS vs Everolimus-Eluting Stent

October 17, 2017

Presentation EuroPCR 2017

ABSORB Japan Results: 3-year Clinical and Angiographic Results

Presenter: Ken Kozuma

May 17, 2017

Presentation EuroPCR 2017

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Presenter: Runlin Gao

May 17, 2017

Presentation SCAI 2017

Absorb Scaffolds Will Be Used In Most Patients One Day

Presenter: Cindy L Grines

May 17, 2017

Presentation

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

April 18, 2017

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

Presentation JIM 2017

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

Presenter: Gregg W. Stone

February 08, 2017

Presentation JIM 2017

ABSORB Lessons From Registries: Outcome Influenced by Experience and Technique

Presenter: Robert-Jan van Geuns

February 08, 2017

Presentation

Efficacy and Safety of the Absorb Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Absorb Diabetic Substudy

Presenter: D. Kereiakes

December 23, 2016

Presentation Cardiovascular Interventions 2016

Understanding the ABSORB Bioresorbable Vascular Scaffold: The Next Revolution in PCI

Presenter: David G. Rizik

November 10, 2016

Presentation TCT 2016

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Runlin Gao

October 30, 2016

Presentation

Mid- to Long-Term Outcomes of Patients Treated With the Absorb Bioresorbable Vascular Scaffold

Presenter: Cordula Felix

July 28, 2016

Presentation

Stent Thrombosis With DES and Absorb Bioresorbable Scaffold

Presenter: S.H. Kang

June 03, 2016

Presentation ACC 2016

Outcomes of the ABSORB Bioresorbable Vascular Scaffold in Very Small and Not Very Small Coronary Arteries: The ABSORB III randomized trial

Presenter: Gregg W. Stone

April 03, 2016

Advertisement

Final seven-year outcome of the COMPARE-ABSORB trial

Myocardial Blood Flow and Coronary Flow Reserve 3 Years After Absorb BVS vs DES: VANISH

ISAR-Absorb MI: A Prospective, Randomized Trial of BVS vs EES in Patients Undergoing Coronary Stenting for Myocardial Infarction

Outcomes of 10.312 Patients Treated with Everolimus-eluting Bioresorbable Scaffolds During Daily Clinical Practice: Results from the European Absorb Consortium

New Fully Absorbable Patch Based Large Hole Vascular Closure Device

Mid- and Long-term Outcome Comparisons of Absorb BVS vs Everolimus-Eluting Stent

ABSORB Japan Results: 3-year Clinical and Angiographic Results

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Absorb Scaffolds Will Be Used In Most Patients One Day

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

ABSORB Lessons From Registries: Outcome Influenced by Experience and Technique

Efficacy and Safety of the Absorb Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Absorb Diabetic Substudy

Understanding the ABSORB Bioresorbable Vascular Scaffold: The Next Revolution in PCI

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Mid- to Long-Term Outcomes of Patients Treated With the Absorb Bioresorbable Vascular Scaffold

Stent Thrombosis With DES and Absorb Bioresorbable Scaffold

Outcomes of the ABSORB Bioresorbable Vascular Scaffold in Very Small and Not Very Small Coronary Arteries: The ABSORB III randomized trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content